Aptorum Group(APM) - 2025 Q2 - Quarterly Report

Merger Agreement and Structure - Aptorum and DiamiR entered into a Merger Agreement on July 14, 2025, with DiamiR becoming a wholly owned subsidiary of Aptorum[65]. - Following the Merger, Aptorum shareholders are expected to own approximately 30% of the outstanding shares of the Combined Company, while DiamiR stockholders are expected to own approximately 70%[69]. - The proposed share consolidation will occur at a ratio of either 2-1, 3-1, or other ratios as determined by the Board[74]. - The Domestication Proposal requires a special resolution with at least two-thirds of the votes cast by Aptorum Class A and Class B shareholders[73]. - The issuance of shares of Aptorum Delaware common stock to DiamiR stockholders will represent more than 20% of the shares outstanding immediately prior to such issuance[77]. - Aptorum plans to change its corporate name to "Niki BioSolutions, Inc." following the Merger[65]. - The approval of the Domestication Proposal is a condition to closing the Merger under the Merger Agreement[73]. - A new stock incentive plan will be implemented with an unspecified number of shares of Common Stock[77]. - Five directors have been proposed for appointment to the Combined Company, effective upon the Closing of the Merger[77]. - The Combined Company board will consist of five members, with three designated by Aptorum and two by DiamiR, including Ian Huen as Chair[88]. - The executive management team post-Merger will include Ian Huen as CEO, Gary Anthony as CFO, and Alidad Mireskandari as President and COO[89]. - The merger agreement includes provisions for DiamiR stockholders to appoint directors to the Combined Company's board, contingent on their ownership percentage[140]. Financial Overview - DiamiR has incurred net losses of $743,235 and $614,405 for the years ended May 31, 2025 and 2024, respectively, with an accumulated deficit of $5,822,571[128]. - DiamiR has raised over $9.7 million in grant funding, including approximately $3.86 million from the NIH for the development of its lead diagnostic product, CogniMIR®[130]. - DiamiR has not generated any revenues from product sales and expects to continue incurring net losses and negative cash flows for the foreseeable future[128]. - DiamiR's valuation at the time of the merger closing is set at $18.7 million, with Aptorum's stock price at $0.94 per share prior to the merger agreement[151]. - The combined company will maintain a cash balance of no less than $2,260,000 and working capital of no less than $1,644,000 at closing, with Aptorum currently holding approximately $2.8 million in cash[174]. - Aptorum has approximately $2.8 million in cash and current assets of approximately $3.0 million as of June 30, 2025, with a target to maintain at least $2,260,000 in unrestricted cash at the closing of the Merger[190]. Strategic Focus and Operations - Aptorum focuses on R&D and has streamlined operations by terminating clinical services and suspending non-lead R&D projects to enhance shareholder value[125]. - Aptorum aims to develop a broad range of therapeutics and diagnostics, focusing on unmet medical needs in oncology and infectious diseases[121]. - The company is actively seeking strategic collaborators to provide financial support and clinical expertise for advancing its therapeutic programs[123]. - Aptorum's lead projects include ALS-4 and SACT-1, with ALS-4 progressing towards IND submission after positive FDA feedback[123]. - The merger is expected to create long-term value through DiamiR's product candidates in brain health, cancer, and inflammatory diseases[153]. - The merger is seen as more favorable than potential alternatives, which could lead to a delisting of Aptorum's Class A ordinary shares from Nasdaq[152]. Regulatory and Approval Considerations - The merger is subject to various conditions, including the approval of the Nasdaq Stock Issuance Proposal and the effectiveness of a registration statement on Form S-4[172]. - The completion of the Merger is subject to regulatory approvals which may delay or prevent consummation[185]. - The Merger will be accounted for under GAAP, with Aptorum as the accounting acquirer and DiamiR as the accounting acquiree[181]. - The time required to obtain approval from regulatory authorities like the FDA and EMA is unpredictable and typically takes many years[244]. - Regulatory authorities may require additional studies or data, delaying approval and commercialization plans for Aptorum's drug candidates[247]. Risks and Challenges - The market price of the Combined Company's shares may decline due to ownership dilution and failure to achieve anticipated benefits from the Merger[196]. - The Combined Company may face significant management challenges and resource allocation issues during the integration process post-Merger[198]. - The company currently does not generate revenue from product sales and may never become profitable without raising additional capital[217]. - The average cost of launching a new drug is estimated to approach $2.6 billion and can take around 12 years to reach the market[221]. - Approximately 86.2% of drug candidates entering phase 1 trials fail to achieve drug approval[221]. - The company has limited financial and managerial resources, focusing on three Lead Projects, which may ultimately prove unsuccessful[227]. - Delays in patient enrollment for clinical trials could result in increased costs and affect the timing or outcome of the trials[233]. - Compliance with current Good Clinical Practices (cGCP) is essential, and failure to comply may render clinical data unreliable[238]. - Clinical trials may be suspended or terminated due to safety issues or non-compliance with regulatory requirements[246]. - Significant clinical trial delays could allow competitors to bring products to market before Aptorum, impairing its commercialization efforts[243]. Management and Governance - Certain officers and directors of Aptorum and DiamiR have interests in the Merger that may differ from those of shareholders, potentially influencing their support for the Merger[194]. - No independent fairness opinion was obtained regarding the Merger, with the consideration reached through negotiations deemed fair by Aptorum's board[195]. - Anti-takeover provisions in the Proposed Charter and Bylaws could make it difficult for stockholders to replace management or initiate beneficial transactions[209]. - The Proposed Charter will designate Delaware courts as the exclusive forum for certain litigation, potentially limiting stockholders' options for judicial recourse[213].